Rinvoq

Chemical Nameupadacitinib
Dosage FormExtended-release tablet (oral; 15 mg)
Drug ClassKinase inhibitors
SystemMusculoskeletal
CompanyAbbVie Inc.
Approval Year2019

Indication

  • Rinvoq is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.
Last updated on 2/1/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Rinvoq (upadacitinib) Prescribing Information 2019Abbvie